Sean Brennan, Shen Chen, Samir Makwana, Simona Esposito, Lauren R. McGuinness, Abrar I. M. Alnaimi, Mark W. Sims, Manish Patel, Qadeer Aziz, Leona Ojake, James A. Roberts, Parveen Sharma, David Lodwick, Andrew Tinker, Richard Barrett-Jolley, Caroline Dart, Richard D. Rainbow
{"title":"Identification and characterisation of functional Kir6.1-containing ATP-sensitive potassium channels in the cardiac ventricular sarcolemmal membrane","authors":"Sean Brennan, Shen Chen, Samir Makwana, Simona Esposito, Lauren R. McGuinness, Abrar I. M. Alnaimi, Mark W. Sims, Manish Patel, Qadeer Aziz, Leona Ojake, James A. Roberts, Parveen Sharma, David Lodwick, Andrew Tinker, Richard Barrett-Jolley, Caroline Dart, Richard D. Rainbow","doi":"10.1111/bph.16390","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Purpose</h3>\n \n <p>The canonical K<sub>ir</sub>6.2/SUR2A ventricular K<sub>ATP</sub> channel is highly ATP-sensitive and remains closed under normal physiological conditions. These channels activate only when prolonged metabolic compromise causes significant ATP depletion and then shortens the action potential to reduce contractile activity. Pharmacological activation of K<sub>ATP</sub> channels is cardioprotective, but physiologically, it is difficult to understand how these channels protect the heart if they only open under extreme metabolic stress. The presence of a second K<sub>ATP</sub> channel population could help explain this. Here, we characterise the biophysical and pharmacological behaviours of a constitutively active K<sub>ir</sub>6.1-containing K<sub>ATP</sub> channel in ventricular cardiomyocytes.</p>\n </section>\n \n <section>\n \n <h3> Experimental Approach</h3>\n \n <p>Patch-clamp recordings from rat ventricular myocytes in combination with well-defined pharmacological modulators was used to characterise these newly identified K<sup>+</sup> channels. Action potential recording, calcium (Fluo-4) fluorescence measurements and video edge detection of contractile function were used to assess functional consequences of channel modulation.</p>\n </section>\n \n <section>\n \n <h3> Key Results</h3>\n \n <p>Our data show a ventricular K<sup>+</sup> conductance whose biophysical characteristics and response to pharmacological modulation were consistent with K<sub>ir</sub>6.1-containing channels. These K<sub>ir</sub>6.1-containing channels lack the ATP-sensitivity of the canonical channels and are constitutively active.</p>\n </section>\n \n <section>\n \n <h3> Conclusion and Implications</h3>\n \n <p>We conclude there are two functionally distinct populations of ventricular K<sub>ATP</sub> channels: constitutively active K<sub>ir</sub>6.1-containing channels that play an important role in fine-tuning the action potential and K<sub>ir</sub>6.2/SUR2A channels that activate with prolonged ischaemia to impart late-stage protection against catastrophic ATP depletion. Further research is required to determine whether K<sub>ir</sub>6.1 is an overlooked target in Comprehensive in vitro Proarrhythmia Assay (CiPA) cardiac safety screens.</p>\n </section>\n </div>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":6.8000,"publicationDate":"2024-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bph.16390","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bph.16390","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and Purpose
The canonical Kir6.2/SUR2A ventricular KATP channel is highly ATP-sensitive and remains closed under normal physiological conditions. These channels activate only when prolonged metabolic compromise causes significant ATP depletion and then shortens the action potential to reduce contractile activity. Pharmacological activation of KATP channels is cardioprotective, but physiologically, it is difficult to understand how these channels protect the heart if they only open under extreme metabolic stress. The presence of a second KATP channel population could help explain this. Here, we characterise the biophysical and pharmacological behaviours of a constitutively active Kir6.1-containing KATP channel in ventricular cardiomyocytes.
Experimental Approach
Patch-clamp recordings from rat ventricular myocytes in combination with well-defined pharmacological modulators was used to characterise these newly identified K+ channels. Action potential recording, calcium (Fluo-4) fluorescence measurements and video edge detection of contractile function were used to assess functional consequences of channel modulation.
Key Results
Our data show a ventricular K+ conductance whose biophysical characteristics and response to pharmacological modulation were consistent with Kir6.1-containing channels. These Kir6.1-containing channels lack the ATP-sensitivity of the canonical channels and are constitutively active.
Conclusion and Implications
We conclude there are two functionally distinct populations of ventricular KATP channels: constitutively active Kir6.1-containing channels that play an important role in fine-tuning the action potential and Kir6.2/SUR2A channels that activate with prolonged ischaemia to impart late-stage protection against catastrophic ATP depletion. Further research is required to determine whether Kir6.1 is an overlooked target in Comprehensive in vitro Proarrhythmia Assay (CiPA) cardiac safety screens.
期刊介绍:
The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries.
Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues.
In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.